fda compounding semaglutide warning letters september 2025 warns Novo Nordisk over GLP-1 medication side effects U.S. FDA sends drug advertising

Because CIV has a greater affinity for NO than oxygen, NO binds to CIV instead of oxygen

Divi's Laboratories is already supplying semaglutide components globally Price compression will occur Not immediately, and not to generic-drug levels, but a ~50% reduction from current branded pricing is a reasonable baseline expectation based on biosimilar precedent in other biologic classes New formulations will compete Novo Nordisk's oral semaglutide (approved December 2025 by the FDA and launched in early 2026) and the newly FDA-approved once-daily oral GLP-1 orforglipron (Foundayo, approved April 1, 2026) represent the manufacturer's strategy for maintaining market share through innovation beyond the injectable The arrival of biosimilar competition does not mean branded products disappear

Fiber boosters: chia seeds, flaxseed, hemp hearts, berries, avocado, vegetables, and fermented foods if tolerated

Watch for signs of gastroparesis

[DOI] [PubMed] [Google Scholar] 43.Choi CI